Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial

Sanjiv J. Shah, John F. Heitner, Nancy K. Sweitzer, Inder S. Anand, Hae Young Kim, Brian Harty, Robin Boineau, Nadine Clausell, Akshay S. Desai, Rafael Diaz, Jerome L. Fleg, Ivan Gordeev, Eldrin F. Lewis, Valetin Markov, Eileen O'Meara, Bondo Kobulia, Tamaz Shaburishvili, Scott D. Solomon, Bertram Pitt, Marc A. PfefferRebecca Li

Research output: Contribution to journalArticle

109 Scopus citations

Abstract

Background-Treatment of Preserved Cardiac Function with an Aldosterone Antagonist (TOPCAT) is an ongoing randomized controlled trial of spironolactone versus placebo for heart failure with preserved ejection fraction (HFpEF). We sought to describe the baseline clinical characteristics of subjects enrolled in TOPCAT relative to other contemporary observational studies and randomized clinical trials of HFpEF. Methods and Results-Between August 2006 and January 2012, 3445 patients with symptomatic HFpEF from 270 sites in 6 countries were enrolled in TOPCAT. At the baseline study visit, all subjects provided a detailed medical history and underwent physical examination, electrocardiography, quality of life, and laboratory assessment. Key parameters were compared with other large, contemporary HFpEF studies. The mean age was 68.6±9.6 years with a slight female predominance (52%); mean body mass index was 32 kg/m2; and comorbidities were common. History of hypertension (91% prevalence in TOPCAT) exceeded all other major HFpEF clinical trials. However, baseline blood pressure was well controlled (129/76 mm Hg; systolic blood pressure 7-16 mm Hg lower than other similar trials). Other common comorbidities included coronary artery disease (57%), atrial fibrillation (35%), chronic kidney disease (38%) and diabetes mellitus (32%). Self-reported activity levels were low, quality of life scores were comparable with those reported for patients with end-stage renal disease, and the prevalence of moderate or greater depression was 27%. Conclusions-TOPCAT subjects share many common characteristics with contemporary HFpEF cohorts. Low activity level, significantly decreased quality of life, and depression were common at baseline in TOPCAT, underscoring the continued unmet need for evidence-based treatment strategies in HFpEF.

Original languageEnglish (US)
Pages (from-to)184-192
Number of pages9
JournalCirculation: Heart Failure
Volume6
Issue number2
DOIs
StatePublished - Mar 2013

Keywords

  • Aldosterone
  • Diastolic heart failure
  • Mineralocorticoid receptor
  • Randomized controlled trial
  • Spironolactone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial'. Together they form a unique fingerprint.

  • Cite this

    Shah, S. J., Heitner, J. F., Sweitzer, N. K., Anand, I. S., Kim, H. Y., Harty, B., Boineau, R., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., Gordeev, I., Lewis, E. F., Markov, V., O'Meara, E., Kobulia, B., Shaburishvili, T., Solomon, S. D., Pitt, B., ... Li, R. (2013). Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation: Heart Failure, 6(2), 184-192. https://doi.org/10.1161/CIRCHEARTFAILURE.112.972794